Core Insights - enGene Holdings Inc. is positioned strongly at the end of 2025, with completed enrollment in the LEGEND pivotal cohort and a cash position of $342.4 million, extending its financial runway into the second half of 2028 [2][9] - The company aims to file a Biologics License Application (BLA) in the second half of 2026, with potential approval anticipated in 2027 [2][14] Financial Performance - For the full year ended October 31, 2025, total operating expenses were $123.2 million, a significant increase from $62.3 million in 2024, primarily due to higher research and development costs [10][24] - The net loss attributable to common shareholders was approximately $117.3 million, or $2.29 per share, compared to a net loss of $55.1 million, or $1.46 per share, for the previous year [11][25] - As of October 31, 2025, cash, cash equivalents, and marketable securities totaled $202.3 million, with an additional $140.1 million raised from a public offering in November [9][26] Clinical Development Updates - The LEGEND pivotal cohort has completed enrollment of 125 patients, exceeding the target by 25%, and has shown a generally favorable tolerability profile [3][4] - Recent data from the LEGEND trial indicated a 63% complete response (CR) rate at any time, with 56% at 3 months and 62% at 6 months for post-baseline assessments [6][17] - The company is also participating in the FDA's Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program, which aims to facilitate the development of therapies with compressed clinical timelines [5][16] Corporate Developments - enGene appointed Hussein Sweiti, M.D., MSc, as Chief Medical Officer, bringing over 15 years of experience in oncology clinical research and drug development [8] - The company successfully closed a public offering of common shares and pre-funded warrants, raising $140.1 million in net proceeds [4]

Summary of enGene Holdings FY Conference Call Company Overview - **Company**: enGene Holdings (NasdaqCM: ENGN) - **Focus**: Non-viral gene therapy utilizing the Dually Derivatized Oligochitosan (DDX) platform - **Lead Asset**: Detalimogene voraplasmid, targeting non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) resistant to Bacillus Calmette-Guérin (BCG) [2][3] Industry Context - **Bladder Cancer Statistics**: - Sixth most common cancer in the U.S. - Approximately 780,000 patients currently, with 82,000 new cases annually [5] - **Current Treatment Landscape**: - BCG is the standard treatment but is often on backorder, leading to radical cystectomy in many cases [5] Core Points and Arguments - **Efficacy and Tolerability**: - Detalimogene voraplasmid shows a 71% complete response (CR) rate with good tolerability [7][10] - Compared to existing products with CR rates of 20% to 40% [8] - **Ease of Administration**: - No pre-washes, special handling, or co-medications required, making it more suitable for busy community urology practices [9][10] - **Protocol Changes in LEGEND Study**: - Implemented three protocol amendments to enhance efficacy, including stricter enrollment criteria for T1 patients and allowing resection of TA [13][16] - **Regulatory Confidence**: - High confidence in the registrational path, supported by FDA engagement and recent designations [20] Competitive Landscape - **Differentiation from Competitors**: - Detalimogene voraplasmid is non-viral, contrasting with newer products that may require complex handling [11][12] - **Market Positioning**: - Targeting community urologists who may not be tracking new medications closely, focusing on the product's efficacy and ease of use [22] Future Outlook - **Clinical Development**: - Anticipated data updates in Q4 of the current year, with a BLA filing expected in mid-next year and potential approval in 2027 [28] - **Cash Position**: - Over $250 million in cash, sufficient to fund operations into 2027 [28] - **Expansion Beyond Bladder Cancer**: - Potential applications of the DDX platform in other cancers and mucosal delivery systems [26][27] Additional Insights - **AI Integration**: - enGene is exploring AI's potential to enhance drug development and commercialization processes [33][34] - **Regulatory Environment**: - Positive interactions with the FDA, indicating a supportive regulatory landscape for enGene's products [35][36] Conclusion - enGene Holdings is positioned to address significant unmet needs in bladder cancer treatment with its innovative non-viral gene therapy platform, demonstrating strong efficacy, tolerability, and ease of use, while maintaining a solid financial position and regulatory support for future growth.